AstraZeneca plc (LON:AZN) Given Consensus Recommendation of “Hold” by Brokerages
AstraZeneca plc (LON:AZN) has received a consensus recommendation of “Hold” from the thirty analysts that are covering the stock. Five equities research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is GBX 4,883.48 ($63.74).
A number of equities analysts have weighed in on AZN shares. Deutsche Bank AG restated a “buy” rating and set a GBX 5,600 ($73.10) price objective on shares of AstraZeneca plc in a research report on Tuesday, May 31st. Berenberg Bank reaffirmed a “buy” rating and set a GBX 4,950 ($64.61) target price on shares of AstraZeneca plc in a report on Thursday, June 9th. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Thursday, June 23rd. Societe Generale reaffirmed a “buy” rating and set a GBX 6,900 ($90.07) target price on shares of AstraZeneca plc in a report on Friday, June 24th. Finally, Bryan, Garnier & Co reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th.
Shares of AstraZeneca plc (LON:AZN) traded up 1.27% during midday trading on Wednesday, reaching GBX 5122.00. 1,719,330 shares of the company were exchanged. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The firm has a 50-day moving average of GBX 5,023.51 and a 200 day moving average of GBX 4,386.43. The firm’s market capitalization is GBX 64.79 billion.
The firm also recently announced a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.